<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Previous studies have suggested that <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> blockade can reduce the incidence of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) or <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) in patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The SPIronolactone to Reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> Therapy (SPIRIT) trial was designed to test the hypothesis that <z:chebi fb="0" ids="9241">spironolactone</z:chebi> reduces the incidence of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> in patients with implantable cardioverter-defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) who are at moderately high risk for recurrent VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Ninety patients who had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> who were at moderately high risk for recurrent VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> and who were not candidates for <z:chebi fb="0" ids="9241">spironolactone</z:chebi> by current <z:hpo ids='HP_0001635'>heart failure</z:hpo> guidelines were randomized to receive <z:chebi fb="0" ids="9241">spironolactone</z:chebi> 25 mg daily or placebo in a double-blind fashion </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had previously received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy (shock or antitachycardia pacing) for VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> within 2 years of randomization or an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> for secondary prevention of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> within 6 months of randomization </plain></SENT>
<SENT sid="4" pm="."><plain>The primary end point was time to first recurrence of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> requiring <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
<SENT sid="5" pm="."><plain>After a median follow-up of 35 months, the Kaplan-Meier probability estimates for VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> requiring <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy were 68.7% in the placebo group and 84.7% in the <z:chebi fb="0" ids="9241">spironolactone</z:chebi> group </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with placebo, <z:chebi fb="0" ids="9241">spironolactone</z:chebi> was associated with a similar risk of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (hazard ratio, 1.01; 95% CI, 0.64-1.83; P=0.71) </plain></SENT>
<SENT sid="7" pm="."><plain>There was no significant difference between the median times to first VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> recurrence requiring <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in the 2 groups </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> who were at moderately high risk for recurrent VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> on account of a recent VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> event that was either sustained or treated by the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> and who were not candidates for <z:chebi fb="0" ids="9241">spironolactone</z:chebi> by current <z:hpo ids='HP_0001635'>heart failure</z:hpo> guidelines, <z:chebi fb="0" ids="9241">spironolactone</z:chebi> did not delay the first recurrence of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> or reduce the risk of recurrent VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
</text></document>